This content is restricted to site members. If you are an existing user, please log in. New users may register below.
May 25, 2025
The SUM Breast Cancer Cell Line Knowledge Base (SLKBase)
Using functional genomics to navigate critical pathways for growth and survival of breast cancer cells
- Welcome Breast Cancer Researchers!
- SLKBase!
- Key features of this cell line panel
- Why is it important to have a breast cancer cell line knowledge base?
- The Omic data sets that were used to develop the SLKBase
- SLKBase functional genomics strategy for the SUM Breast cancer cell lines
- Functional Druggable Signatures for the SUM cell lines
- See what we’re working on to make the Knowledge Base better
- SUM Cell Lines Gateway Page
- About Steve Ethier
- Blog posts on the SUM breast cancer cell lines
- SUM line media and protocols
- Please join the SLKBase email list on MailChimp
- Gateway to the SUM Breast Cancer Cell Lines
- SUM-44 Home
- The Story of the SUM-44PE cell line
- Bibliography of published papers in which SUM-44 cells were used
- Narrative summary of molecular and cellular characteristics of the SUM-44PE cells
- Oncogenes and Candidate Oncogenes in SUM-44PE cells
- The KEGG canonical pathways enriched with data from our genome-scale shRNA screen in SUM-44 cells
- SUM-44 cells: Functional-druggable signature
- Drug Sensitivity Data for functional-druggable targets of SUM-44 cells
- STR Profile for SUM-44 cells
- SUM-52 Home
- Derivation of the SUM-52PE breast cancer cell line
- Bibliography of published papers in which SUM-52 cells were used
- Narrative Summary of the SUM-52PE cell line
- The Oncogenes of the SUM-52PE breast cancer cell line
- The KEGG canonical pathways enriched with data from our genome-scale shRNA screen with SUM-52 cells
- SUM-52 Cell Cycle pathway
- SUM-52 PI3’K/AKT pathway
- SUM-52 WNT pathway
- SUM-52 Hippo Pathway
- SUM-52 Apoptosis
- SUM-52 MAPK signaling
- SUM-52 ECM-Receptor Interaction
- SUM-52 Cytokine-Cytokine Receptor Interaction
- SUM-52 mTOR Pathway
- SUM-52 Breast Cancer Pathway
- SUM-52 Signaling Pathways Regulating Pluripotency of Stem Cells
- SUM-52 Cells: Functional Druggable Signature
- SUM-52 Differential drug sensitivity data
- SUM-102 Home
- Characteristics of the patient specimen from which SUM-102 was derived
- SUM-102 Bibliography
- The KEGG canonical pathways enriched with data from our genome-scale shRNA screen
- Narrative Summary of the SUM-102 Cell Line
- The Candidate Oncogene Signature for SUM-159 cells.
- SUM-102 cells: Functional-druggable Signature
- STR Profile for SUM-102 cells
- SUM-149 Home
- Characteristics of the patient from which SUM-149PT was derived
- SUM-149 Bibliography
- Narrative Summary of the SUM-149 Cell Line
- Functional amplified oncogenes in SUM-149PT cells
- Mutational Oncogene Signature of SUM-149PT cells
- KEGG canonical pathways enriched with data from the genome scale shRNA screen
- SUM-149 Cells: Functional-druggable Signature
- SUM-149 Differential Drug Sensitivity Data
- SUM-159 Home
- SUM-185PE Home
- Derivation of the SUM-185PE cell line
- SUM-185PE Bibliograpy
- Narrative Summary of the SUM-185PE cell line
- SUM-185 Candidate Oncogene Signature
- Cancer Gene mutational signature for SUM-185
- KEGG pathways enriched with screen hit data for SUM-185
- SUM-185 cells: Functional-druggable signature
- SUM-185 Differential Drug Sensitivity (uM)
- SUM-190 Home
- Characteristics of the patient from which SUM-190 was derived and derivation of the cell line
- SUM-190 Bibliography
- The SUM-190 Candidate Oncogene Signature
- The point mutational oncogene signature of SUM-190
- Narrative Summary of the SUM-190 Cell Line
- The KEGG canonical pathways enriched with data from our genome-scale shRNA screen
- SUM-190 Cells: Functional-druggable Signature
- SUM-225 Home
- SUM-225 Characteristics of the patient from which SUM-225 was derived
- SUM-225 Bibliograpy
- SUM-225 Candidate Oncogene Signature
- SUM-225 point mutational oncogene signature
- SUM-225 KEGG pathways enriched with data from the genome-scale shRNA screen
- SUM-225 Cell cycle
- SUM-225 ERBB signaling
- SUM-225 PI3’K/AKT signaling
- SUM-225 MAPK signaling
- SUM-225 Apoptosis signaling
- SUM-225 FOXO signaling
- SUM-225 Hedgehog Signaling
- SUM-225 HIF-1 Signaling
- SUM-225 TGF-beta signaling
- SUM-225 RAS signaling
- SUM-225 mTOR signaling
- SUM-225 WNT signaling
- SUM-225 Hippo Signaling
- SUM-225 Signaling pathways regulating pluripotency in stem cells
- SUM-225 Cells: Functional-druggable Signature
- STR Profile for SUM-225 cells
- SUM225 differential drug sensitivity data
- SUM-229 Home
- SUM-1315 Home
- Derivation of the SUM-1315 breast cancer cell line
- SUM-1315 Bibliograpy
- The Candidate Oncogene Signature of the SUM-1315 cell line and other interesting data
- The KEGG canonical pathways enriched with data from our genome-scale shRNA screen
- SUM1315 cells: Functional-druggable signature
- SUM-1315 Differential Drug Sensitivity Data (uM)
- SUM-44 Home
- Data mining tools for the SUM breast cancer cell lines
- Oncogene Signature Tool
- SUM-line KEGG pathway engine
- KEGG Pathway Analysis tool:
- KEGG Pathway Druggable Functional Pathway Analysis:
- Sum Line Gene Query
- Proteomics and Phophoproteomic data for the SUM breast cancer cell line
- Proteomic analysis of the SUM cell lines. Graphs of key proteins
- Unsupervised cluster analysis of the RPPA results derived from the SUM cell lines
- ER, AR, and GATA 3 expression in the SUM lines
- AKT-pS308, AKT-pT473, PTEN, RPS6, RPS6-pS235, RPS6-pS240
- Annexin1, Notch1, Taz, Mct4, Sox2, Vhl-Eppk1
- Bcl2, Bcl-xL, MCL1, Bid, Bim
- beta-catenin, p53, c-Myc, Brd4, Prex1
- Caveolin1, connexin43, E-cadherin, EMA, FN1
- CyclinD1, CyclinD3, GAB2
- Dusp4, p16ink4, Pai-1, p21, Rad51, Fasn
- Her2, HER2 (minus amplified cell lines), Her3, Egfr
- PKCa, Syk, Axl
- Src, Src-pY416, Src-pY527, p38Mapk, Shc-pY317, Shp2 pY542
- Vegfr2, Igfbp2, Ndrg1, Met-pY1234
- Gateway to 40 Breast Cancer Cell Lines
- AU565 Breast Cancer Cell Line
- The BT549 breast cancer cell line
- The CAL51 Breast Cancer Cell Line
- The CAMA1 Breast Cancer Cell Line
- The EFM19 Breast Cancer Cell Line
- The DU4475 Breast Cancer Cell Line
- The BT20 Breast Cancer Cell Line
- The CAL120 Breast Cancer Cell line
- The HCC70 Breast Cancer Cell Line
- The HCC202 Breast Cancer Cell Line
- The HCC1143 Human Breast Cancer Cell Line
- The HCC1187 Breast Cancer Cell Line
- The HCC1395 Breast Cancer Cell Line
- The HCC1419 Breast Cancer Cell Line
- The HCC1428 Breast Cancer Cell Line
- The HCC1500 Breast Cancer Cell Line
- The HCC1569 Breast Cancer Cell Line
- The HCC1806 Breast Cancer Cell Line
- The HCC1937 Breast Cancer Cell Line
- The HCC1954 Breast Cancer Cell Line
- The HCC2218 Breast cancer cell line
- The HMC18 breast cancer cell line
- The Hs578T breast cancer cell line
- The JIMT1 Human breast cancer cell line
- The KPL1 Breast Cancer Cell Line
- The MCF-7 Human Breast Cancer Cell Line
- The MDA-MB-231 Breast Cancer Cell Line
- The MDA-MB-468 breast cancer cell line
- The MDA-MB-134VI breast cancer cell line
- The MDA-MB-175VII breast cancer cell line
- The MDA-MB-157 breast cancer cell line
- The MDA-MB-361 Breast Cancer Cell Line
- The MDA-MB-415 breast cancer cell line
- The MDA-MB-436 breast cancer cell line
- The MDA-MB-453 breast cancer cell line
- The SKBR3 breast cancer cell line
- The T47D breast cancer cell line
- The UACC812 breast cancer cell line
- The ZR7530 breast cancer cell line
- The ZR751 breast cancer cell line
- Data Mining Tools for the Additional Breast Cancer Cell Lines
- Data Mining Tools for all cancer cell lines
- The SLKBase BLOG!
- YouTube Video and Data Download Center
- HOW TO ACQUIRE THE SUM BREAST CANCER CELL LINES
- The Biology of Cancer: A Course for Everyone
Comments are closed.